As i wrote in May, my concerns were about the non-clinical data.
Since it was obviously one of the six questions it is obvious that PAR did not address it properly.
From what i gathered they used a nuke dosage level.
So here is what they need to do.
Point out it was a nuke, and make sure they deal with
"what could possibly go wrong"
which is what any half-decent project manager would have done in the first place
(implication for PAR, run another non-clinical trial with three different dosage levels)
Have PR resign from one of his two roles (that's not a new one from me).
Start talking to EU (just once b4).
Not take thirty days to respond, with what appears to be not answers to the actual questions.
- Forums
- ASX - By Stock
- Interview with an FDA Process Expert - Pre Questions
As i wrote in May, my concerns were about the non-clinical...
Featured News
Add PAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
24.5¢ |
Change
-0.010(3.92%) |
Mkt cap ! $85.70M |
Open | High | Low | Value | Volume |
24.5¢ | 25.0¢ | 24.0¢ | $59.66K | 241.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 78837 | 24.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
25.0¢ | 36290 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 78837 | 0.245 |
3 | 44840 | 0.240 |
5 | 111000 | 0.235 |
5 | 125200 | 0.230 |
6 | 135884 | 0.225 |
Price($) | Vol. | No. |
---|---|---|
0.255 | 46689 | 5 |
0.260 | 106349 | 3 |
0.265 | 30000 | 1 |
0.270 | 20000 | 2 |
0.275 | 13636 | 2 |
Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online